natgillin/translations-raw huggingface dataset:
Cmax: ↑ 14 % (↑ 4 to ↑ 26)
Cmax: ↑ 14% (↑ 4...↑ 26)
Cmax: ↑ 14% (↑ 4 to ↑ 26)
Cmax: ↑ 14% (↑ 4...↑ 26)
Cmax: ↑ 14% Norenthrindone AUCinf: ↑ 16%
Cmax: ↑ 14% Norentrindoon AUCinf: ↑ 16
Cmax: ↑ 15% (CYP3A4 inhibition)
Cmax: ↓ 15% (CYP3A4 inhibeerimine)
Cmax: ↑ 16 % (↑ 2 to ↑ 32)
Cmax: ↑ 16% (↑ 2...↑ 32)
Cmax: ↑ 16 % (↑ 6 to ↑ 26)
Cmax: ↑ 16% (↑ 6...↑ 26)
Cmax: ↑ 16% (↑ 2 to ↑ 32)
Cmax: ↑ 16% (↑ 2...↑ 32)
Cmax: ↑ 16% (↑ 6 to ↑ 26)
Cmax: ↑ 16% (↑ 6...↑ 26)
Cmax: ↑ 17 %* (↑ 8 to ↑ 27)
Cmax: ↑ 17%* (↑ 8...↑ 27)
Cmax: ↑ 17%* (↑ 8 to ↑ 27) Cmin: ↓ 42%* (↓ 31 to ↓ 51)
Cmin: ↓ 42%* (↓ 31...↓ 51)
Cmax: ↑ 2.7-fold
AUC: ↑ 5,9 korda Cmax: ↑ 2,7 korda
Cmax: ↑ 21 % (↑ 10 to ↑ 33)
Cmax: ↑ 21% (↑ 10...↑ 33)
Cmax: ↑ 21% (↑ 10 to ↑ 33)
Cmax: ↑ 21% (↑ 10...↑ 33)
Cmax: ↑ 23 % (↓ 1 to ↑ 53) *
Cmax: ↑ 23% (↓ 1...↑ 53)
Cmax: ↑ 23% (↓ 1 to ↑ 53) *
Cmax: ↑ 23% (↓ 1...↑ 53)
Cmax: ↑ 3.0 fold
Cmax: ↑ 3,0 korda
Cmax: ↑ 3.4-fold
AUC: ↑ 6,2 korda Cmax: ↑ 3,4 korda
Cmax: ↑ 3.5-fold
AUC: ↑ 5,7 korda
Cmax: ↑ 3.5-fold
Cmax: ↑ 3.5 korda
Cmax: ↑ 30% Inhibition of CYP3A
Cmax: ↑ 30% CYP3A inhibitsioon
Cmax: ↑ 38 %
Cmax: ↑ 38
Cmax: ↑ 38% (competitive inhibition of oxidative metabolism)
Cmax: ↑ 38% (oksüdatiivse metabolismi konkureeriv
Cmax: ↑ 4.1-fold Sirolimus (rapamycin): AUC: ↑ 10.9-fold Cmax: ↑ 4.4-fold
Siroliimus (rapamütsiin): AUC: ↑ 10,9 korda Cmax: ↑ 4,4 korda
Cmax: ↑ 4.7-fold
AUC: ↑ 11 korda
Cmax: ↑ 4.7-fold
Cmax: ↑ 4,7 korda
Cmax: ↑ 47% (↑ 37 – ↑ 58)
Cmax: ↑ 47% (↑ 37 kuni ↑ 58)
Cmax: ↑ 49% (↑ 32 to ↑ 69)
Cmax: ↑ 49% (↑32...↑ 69)
Cmax: ↑ 49% (↑ 32 to ↑ 69) Efavirenz:
Cmax: ↑ 49% (↑ 32...↑ 69) Efavirens:
Cmax: ↑ 5% (↓ 3 to ↑ 14) Cmin: NC
Cmax: ↑ 5% (↓ 3 kuni ↑ 14) Cmin: NC
Cmax: ↑ 5-fold
Rosuvastatiin: AUC: ↑ 2 korda
Cmax: ↑ 50% (↑ 20 to ↑ 80) (CYP2B6 induction)
Cmax: ↑ 50% (↑ 20...↑ 80) (CYP2B6 indutseerimine)
Cmax: ↑ 55%
Cmax : ↑ 55
Cmax: ↑ 6-fold
Cmax: 6-kordne ↑
Cmax: ↑ 6-fold
Tsüklosporiin,
Cmax: ↑ 64% (mechanism of interaction unknown)
Cmax: ↑ 64% (koostoime mehhanism on teadmata)
Cmax: ↑ 7% (↓ 6 to ↑ 22) Cmin: NC
Cmax: ↑ 7% (↓ 6 kuni ↑ 22) Cmin: NC
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmax: ↑ 79% (↑ 56 kuni ↑ 104)
Cmax: ↑ 97%
Cmax : ↑ 97
Cmax: ↑1.6-fold
Cmax: ↑ 1,6 korda
Cmax: ↑89%
Buprenorfiini Cmax ↑37
Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NC
Cmax: ↓ 1% (↓ 7 kuni ↑ 6) Cmin: NC
Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NC
Cmax: ↓ 11% (↓ 17 kuni ↓ 5) Cmin: NC
Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NC
Cmax: ↓ 11% (↓ 20 kuni ↑ 1) Cmin: NC
Cmax: ↓ 12 % (↓ 1 to ↓ 26) 2-hydroxy atorvastatin:
Cmax: ↓ 12% (↓ 1...↓ 26) 2-hüdroksüatorvastatiin:
Cmax: ↓ 12% (↓ 1 to ↓ 26)
Cmax: ↓ 12% (↓ 1...↓ 26)
Cmax: ↓ 12% R-warfarin
Cmax: ↓ 12% R-varfariin
Cmax: ↓ 13 % (↓ 0 to ↓ 23) 4-hydroxy atorvastatin: AUC: ↓ 4 % (↓ 0 to ↓ 31)
Cmax: ↓ 13% (↓ 0...↓ 23) 4-hüdroksüatorvastatiin: AUC: ↓ 4% (↓ 0...↓ 31)
Cmax: ↓ 13% (↓ 0 to ↓ 23)
Cmax: ↓ 13% (↓ 0...↓ 23)
Cmax: ↓ 13% (↓ 0 to ↓ 23) 4-hydroxy atorvastatin: AUC: ↓ 4% (↓ 0 to ↓ 31)
Cmax: ↓ 13% (↓ 0...↓ 23) 4-hüdroksüatorvastatiin: AUC: ↓ 4% (↓ 0...↓ 31)
Cmax: ↓ 14% (↓ 3 to ↓ 24)
C12: ↓ 21
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmax: ↓ 14% (↓ 3 kuni ↓ 24)
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmax: ↓ 14% (↓ 3…↓ 24)
Cmax: ↓ 15% (CYP3A4 induction) Efavirenz:
Cmax: ↓ 15% (CYP3A4 indutseerimine) Efavirens:
Cmax: ↓ 16% (↓ 22 to ↓ 10)
Cmax: ↓ 16% (↓ 22 kuni ↓ 10)
Cmax: ↓ 18 % (↓ 59 to ↑ 12)
Cmax: ↓ 18% (↓ 59...↑ 12)
Cmax: ↓ 18 % (↓ 59 to ↑ 12)
Metadoon:
Cmax: ↓ 18% (↓ 59 to ↑ 12)
Cmax: ↓ 18% (↓ 59...↑ 12)
Cmax: ↓ 19% (↓ 40 – ↑ 10)
Cmax: ↓ 19% (↓ 40 kuni ↑ 10)
Cmax: ↓ 20 % (↓ 11 to ↓ 28)
Cmax: ↓ 20% (↓ 11...↓ 28)
Cmax: ↓ 20 % (↓ 11 to ↓ 28)
Cmax: ↓ 37% (↓ 20...↓ 51)
Cmax: ↓ 20 % (↓ 15 to ↓ 24)
Cmax: ↓ 20% (↓ 15...↓ 24)
Cmax: ↓ 20 % (↓ 15 to ↓ 24)
Cmax: ↓ 64% (↓ 57...↓ 69)
Cmax: ↓ 20 % (↓ 2 to ↓ 26)
2 nädala jooksul hoolikalt
Cmax: ↓ 20 % (↓ 2 to ↓ 26)
Cmax: ↓ 20% (↓ 2...↓ 26)
Cmax: ↓ 20% (↓ 11 to ↓ 28)
Cmax: ↓ 20% (↓ 11...↓ 28)
Cmax: ↓ 20% (↓ 15 to ↓ 24)
Cmax: ↓ 20% (↓ 15...↓ 24)
Cmax: ↓ 20% (↓ 2 to ↓ 26)
Cmax: ↓ 20% (↓ 2...↓ 26)
Cmax: ↓ 21 % (↓ 15 to ↓ 26)
Cmax: ↓ 21% (↓ 15...↓ 26)
Cmax: ↓ 21 % (↓ 15 to ↓ 26)
Cmax: ↓ 28% (↓ 7...↓ 44)
Cmax: ↓ 21% (↓ 15 to ↓ 26)
Cmax: ↓ 21% (↓ 15...↓ 26)
Cmax: ↓ 21% Dihydroartemisinin (active metabolite):
Dihüdroartemisiniin (aktiivne metaboliit):
Cmax: ↓ 21% Dihydroartemisinin:
Sertraliin:
Cmax: ↓ 21% Dihydroartemisinin: AUC: ↓ 46%
Cmax: ↓ 21% Dihüdroartemisiniin: AUC: ↓ 46
Cmax: ↓ 23%
C: ↓ 23
Cmax: ↓ 23% (↓ 30 – ↑ 16)
Cmax: ↓ 23% (↓ 30 kuni ↑ 16)
Cmax: ↓ 23% Cmin, ss: ↓ 16%a) Ritonavir:
Cmax: ↓ 23% Cmin, ss: ↓ 16%a) Ritonavir: AUCtau: ↓ 31
Cmax: ↓ 23% Cmin, ss: ↓ 16%a) Ritonavir: AUCtau: ↓ 31%
Cmax: ↓ 23% Cmin, ss: ↓ 16% ) Ritonavir: AUCtau: ↓ 31
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmax: ↓ 24% (↓ 15 kuni ↓ 32)
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmax: ↓ 24% (↓ 15…↓ 32)
Cmax: ↓ 24% (↓ 18 to ↓ 30)
Cmax: ↓ 24% (↓ 18...↓ 30)
Cmax: ↓ 24% (↓ 44 to ↓ 12) Cmin: NC
Cmax: ↓ 24% (↓ 44 kuni ↓ 12) Cmin: NC
Cmax: ↓ 26 % (↓ 15 to ↓ 35)
Cmax: ↓ 26% (↓ 15...↓ 35) Klaritromütsiini
Cmax: ↓ 26 % (↓ 15 to ↓ 35) Clarithromycin
Cmax: ↓ 26% (↓ 15...↓ 35) Klaritromütsiini
Cmax: ↓ 26% (↓ 15 to ↓ 35)
Cmax: ↓ 26% (↓ 15...↓ 35)
Cmax: ↓ 28 % (↓ 7 to ↓ 44)
Cmax: ↓ 28% (↓ 7...↓ 44)
Cmax: ↓ 28% (↓ 50 to ↑ 5)
Cmax: ↓ 28% (↓ 50...↑ 5)
Cmax: ↓ 28% (↓ 50 – ↑ 5)
Cmax: ↓ 28% (↓ 50...↑ 5)
Cmax: ↓ 28% (↓ 7 to ↓ 44)
Cmax: ↓ 28% (↓ 7...↓ 44)
Cmax: ↓ 29 % (↓ 15 to ↓ 40)
AUC: ↓ 35% (↓ 13...↓ 40)
Cmax: ↓ 29 % (↓ 15 to ↓ 40)
Cmax: ↓ 29% (↓ 15...↓ 40)
Cmax: ↓ 29% (↓ 15 to ↓ 40)
Cmax: ↓ 29% (↓ 15...↓ 40)
Cmax: ↓ 32% (↓ 15 to ↓ 46)
Cmax: ↓ 32% (↓ 15...↓ 46)
Cmax: ↓ 33% (Mechanism unknown)
Cmax: ↓ 33% (mehhanism ei ole teada) Isavukonasool:
Cmax: ↓ 34% (↓ 21 to ↓ 47) Hydroxybupropion:
Cmax: ↓ 34% (↓ 21 kuni ↓ 47) Hüdroksübupropioon:
Cmax: ↓ 34% (↓ 21 to ↓ 47) Hydroxybupropion:
Cmax: ↓ 51% (↓ 32...↓ 58)
Cmax: ↓ 34% (↓ 41 to ↑ 25)
Cmax: ↓ 34% (↓ 41 kuni ↑ 25)
Cmax: ↓ 35 % (↓ 12 to ↓ 52)
Cmax: ↓ 35% (↓ 12...↓ 52)
Cmax: ↓ 35% (↓ 12 to ↓ 52)
Cmax: ↓ 35% (↓ 12...↓ 52)
Cmax: ↓ 36% (UGT1A1 induction)
Cmax: ↓ 36
Cmax: ↓ 37 % (↓ 20 to ↓ 51)
Cmax: ↓ 37% (↓ 20...↓ 51)
Cmax: ↓ 37 % (↓ 20 to ↓ 51)
Cmax: ↓ 61
Cmax: ↓ 37% (↓ 20 to ↓ 51)
Cmax: ↓ 37% (↓ 20...↓ 51)
Cmax: ↓ 37% (↓ 48 – ↓ 25)
Cmax: ↓ 37% (↓ 48 kuni ↓ 25)
Cmax: ↓ 4% (↓ 9 to ↑ 2) Cmin: NC
Cmax: ↓ 4% (↓ 9 kuni ↑ 2) Cmin: NC
Cmax: ↓ 44% (↓ 20 to ↓ 61) Proguanil:
Cmax: ↓ 44% (↓ 20 kuni ↓ 61) Proguaniil:
Cmax: ↓ 45 % (UDP-G induction)
Cmax: ↓ 45
Cmax: ↓ 45 % (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25...↓ 59)
Cmax: ↓ 45 % (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25...↓ 59) (CYP3A4 indutseerimine)
Cmax: ↓ 45 % (↓ 25 to ↓ 59) (CYP3A4 induction)
Ravimid terapeutilise rühma järgi (annus)
Cmax: ↓ 45% (UDP-G induction)
Cmax: ↓ 45
Cmax: ↓ 45% (UDP-G induction)
Cmax: ↓ 45% (UDP-G induktsioon)
Cmax: ↓ 45% (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25...↓ 59)
Cmax: ↓ 45% (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25...↓ 59) (CYP3A4 indutseerimine)
Cmax: ↓ 46 % (↓ 39 to ↓ 52)
Cmax: ↓ 46% (↓ 39…↓ 52)
Cmax: ↓ 46% (↓ 39 to ↓ 52)
Cmax: ↓ 46% (↓ 39…↓ 52)
Cmax: ↓ 47 % (↓ 9 to ↓ 51)
Cmax: ↓ 47% (↓ 9...↓ 51)
Cmax: ↓ 47% (↓ 9 to ↓ 51)
Cmax: ↓ 47% (↓ 9...↓ 51)
Cmax: ↓ 5% (↓ 11 to ↑ 1) Cmin: NC
Cmax: ↓ 5% (↓ 11 kuni ↑ 1) Cmin: NC
Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC
Cmax: ↓ 5% (↓ 27 kuni ↑ 24) Cmin: NC
Cmax: ↓ 51 % (↓ 32 to ↓ 58)
Cmax: ↓ 51% (↓ 32...↓ 58)
Cmax: ↓ 51% (↓ 32 to ↓ 58)
Cmax: ↓ 51% (↓ 32...↓ 58)
Cmax: ↓ 51% (↓ 46 to ↓ 56)
Cmax: ↓ 51% (↓ 46…↓ 56)
Cmax: ↓ 53%
glükokortikoidide
Cmax: ↓ 6% (↓ 13 to ↑ 0)
Cmax: ↓ 6% (↓ 13 kuni ↑ 0)
Cmax: ↓ 60 % (↓ 50 to ↓ 68)
Cmax: ↓ 60% (↓ 50...↓ 68)
Cmax: ↓ 60% (↓ 50 to ↓ 68)
Cmax: ↓ 60% (↓ 50...↓ 68)
Cmax: ↓ 61 %
Cmax: ↓ 61
Cmax: ↓ 61% Efavirenz: AUC: ↑ 44%
Cmax: ↓ 61% Efavirens: AUC: ↑ 44
Cmax: ↓ 62% (↓ 55 to ↓ 78) (CYP3A4 induction)
Cmax: ↓ 62% (↓ 55...↓ 78) (CYP3A4 indutseerimine)
Cmax: ↓ 64 % (↓ 57 to ↓ 69)
Cmax: ↓ 64% (↓ 57...↓ 69)
Cmax: ↓ 64% (↓ 57 to ↓ 69)
Cmax: ↓ 64% (↓ 57...↓ 69)
Cmax: ↓ 7% (↓ 13 to ↓ 0) Cmin: NC
Cmax: ↓ 7% (↓ 13 kuni ↓ 0) Cmin: NC
Cmax: ↓ 7% (↓ 22 to ↑ 11) Cmin: NC
Cmax: ↓ 7% (↓ 22 kuni ↑ 11) Cmin: NC
Cmax: ↓ 76 % (↓ 63 to ↓ 79) Simvastatin acid:
Cmax: ↓ 76% (↓ 63...↓ 79) Simvastatiinhape:
Cmax: ↓ 76 % (↓ 63 to ↓ 79) Simvastatin acid:
ning tekkisid opiaadi ärajätunähud.
Cmax: ↓ 76% (↓ 63 to ↓ 79)
Cmax: ↓ 76% (↓ 63...↓ 79)
Cmax: ↓ 76% (↓ 63 to ↓ 79) Simvastatin acid:
Cmax: ↓ 76% (↓ 63...↓ 79) Simvastatiinhape:
Cmax: ↓ 80 % (↓ 77 to ↓ 83)
Cmax: ↓ 80% (↓ 77…↓ 83)
Cmax: ↓ 80% (↓ 77 to ↓ 83)
Cmax: ↓ 80% (↓ 77…↓ 83)
Cmax: ↔
Fusidiinhape:
Cmax: ↔
kokkuvõte).
Cmax: ↔
Võib
Cmax: ↔ 11% (CYP3A induction - effect on boceprevir)
Cmax: ↔ 11% (CYP3A indutseerimine – toime avaldub botsepreviiril)
Cmax: ↔ 11% (CYP3A induction - effect on boceprevir)
Cmax: ↔ 11% (CYP3A indutseerimine – toime botsepreviirile)
Cmax: ↔ C12 : ↓ 30%
Cmax: ↔ C12: ↓ 30
Cmax: ↔ Cmin: ↔ Efavirenz: AUC: ↔
Cmax: ↔ Cmin: ↔ Efavirens: AUC: ↔
Cmax: ↔ Cmin: ↔ Indinavir:
Cmax: ↔ Cmin: ↔ Indinaviir:
Cmax: ↔ Cmin: ↔ Tenofovir:
Cmax: ↔ Cmin: ↔ Tenofoviir:
Cmax: ↔ Cmin: ↔ Tenofovir: AUC: ↔
Cmax: ↔ Cmin: ↔ Tenofoviir AUC: ↔
Cmax: ↔ Cmin: ↔ Tenofovir: AUC: ↔
Cmax: ↔ Cmin: ↔ Tenofoviir: AUC: ↔
Cmax: ↔ Ketoconazole AUC: ↑ 2.7-fold Cmax:↑ 1.5-fold (CYP3A4 enzyme inhibition by ritonavir)
Cmax: ↔ Ketokonasool AUC: ↑ 2,7 korda Cmax: ↑ 1,5 korda (CYP3A4 ensüümi inhibeerimine ritonaviiri poolt)
Cmax: ↔ Tenofovir: AUC: ↔
Cmax: ↔ Tenofoviir: AUC: ↔
Cmax= maximum plasma concentration t1/2 effective= effective half-lives aValues are estimated from population PK analysis bN=353 refers to all the subjects included in the population PK analysis cValues are obtained from published data [Schaaf LJ et al.
Cmax = maksimaalne plasmakontsentratsioon efektiivne t1/2 = efektiivsed poolväärtusajad a Väärtused on populatsiooni farmakokineetika analüüsi alusel hinnangulised. bN = 353 viitab kõigile populatsiooni farmakokineetika analüüsis osalejatele c Väärtused on hangitud avaldatud andmetest [Schaaf LJ et al.
CMF on day 1 and 8 every 4 weeks for 3 cycles
CMF 1. ja 8. päeval iga 4 nädala järel 3 tsükli jooksul,
CMH test p-value for response rate (versus imatinib 400 mg once daily)
CMH testi p-väärtus ravivastuse määra hindamiseks (võrreldes imatiniibiga 400 mg üks kord ööpäevas)
Cmin (mg/dl)/(mg/kg) (trough level)
Cmin (mg/dl)/(mg/dl) (minimaalne tase)
Cmin (trough, g/l)
Cmin (madalaim, g/l)
Cmin 0.32 (0.25-0.42)
Cmin 0,32 (0,25…0,42)
Cmin 0.44 (0.40-0.50)
Cmin 0,44 (0,40-0,50)
Cmin 0.48 (0.40-0.56)
Cmin 0,48 (0,40...0,56)
Cmin 0.53 (0.44-0.65)
Cmin 0,53 (0,44…0,65)
Cmin 0.58 (0.52-0.64) mechanism unknown
Cmin 0,58 (0,52…0,64) mehhanism teadmata
Cmin 0.67 (0.63-0.71)
Cmin 0,67 (0,63...0,71)
Cmin 0.68 (0.63-0.74)
Cmin 0,68 (0,63…0,74)
Cmin 0.70 (0.64-0.77)
Cmin 0,70 (0,64-0,77)
Cmin 0.70 (0.64-0.77)
Cmin 0,70 (0,64...0,77)
Cmin 0.75 (0.61-0.92)
Cmin 0,75 (0,61…0,92)
Cmin 0.75 (0.66-0.86)
Cmin 0,75 (0,66...0,86)
Cmin 0.85 (0.75-0.98)
Cmin 0,85 (0,75…0,98)
Cmin 0.89 (0.67-1.18)
Cmin 0,89 (0,67…1,18)
Cmin 0.90 (0.81-1.01)
Cmin 0,90 (0,81...1,01)
Cmin 1.03 (0.93-1.14)
Cmin 1,03 (0,93...1,14)
Cmin 1.06 (0.87-1.30)
Cmin 1,06 (0,87...1,30)
Cmin 1.14 (1.04-1.26)
Cmin 1,14 (1,04...1,26)
Cmin 1.41 (1.29-1.54) effect on P-gp transport in the gut
Cmin 1,41 (1,29...1,54) toime P-gp transpordile soolestikus
Cmin 1.78 (1.26-2.53)
Cmin 1,78 (1,26...2,53)
Cmin 1.85 (1.40-2.44)
Cmin 1,85 (1,40…2,44)
Cmin 1.93 (1.55-2.41)
Cmin 1,93 (1,55…2,41)
Cmin : 0 40%
Cmin: O 40
Cmin : ↓ 31 %
Cmin: ↓ 31
Cmin = the observed plasma concentration at the end of the dose interval. bid = twice daily tid = three times daily
Cmin = annustamise intervalli lõpus kindlaks tehtud plasmakontsentratsioon.
Cmin ↑ 1.22 (0.86-1.74)
Cmin ↑ 1,22 (0,86…1,74)
Cmin ↑ 1.24 (0.96-1.59)
Cmin ↑ 1,24 (0,96…1,59)
Cmin ↑ 1.26 (1.12-1.42)
Cmin ↑ 1,26 (1,12…1,42)
Cmin ↑ 1.28 (1.13-1.45)
Cmin  1,28 (1,13…1,45) Cmax ↔ 1,07 (1,02…1,13)
Cmin ↑ 1.77 (1.39-2.25)
Cmin ↑ 1,77 (1,39…2,25)
Cmin ↑ 5.27 (4.51-6.15)
Cmin ↑ 5,27* (4,51…6,15)
Cmin ↓ 0.12 (0.09-0.16)
Cmin ↓ 0,12 (0,09…0,16)
Cmin ↓ 0.18 (0.13-0.25)
Cmin ↓ 0,18 (0,13…0,25)
Cmin ↓ 0.51 (0.44-0.61)
Cmin ↓ 0,51 (0,44…0,61)
Cmin ↓ 0.55 (0.49-0.62)
Cmin ↓ 0,55 (0,49…0,62)
Cmin ↓ 0.61 (0.53-0.71)
Cmin ↓ 0,61 (0,53…0,71)
Cmin ↓ 0.62 (0.55-0.71)
Cmin ↓ 0,62 (0,55…0,71)
Cmin ↓ 0.63 (0.52-0.77)
Cmin ↓ 0,63 (0,52…0,77) Cmax ↓ 0,88 (0,78…1,00)
Cmin ↓ 0.65 (0.56-0.74)
Cmin ↓ 0,65 (0,56…0,74)
Cmin ↓ 0.66 (0.34-1.26)
Cmin ↓ 0,66 (0,34…1,26)
Cmin ↓ 0.71 (0.58-0.87)
Cmin ↓ 0,71 (0,58…0,87)
Cmin ↓ 0.75 (0.61-0.92)
Cmin ↓ 0,75 (0,61…0,92)
Cmin ↓ 0.78 (0.68-0.90)
Cmin ↓ 0,78 (0,68…0,90)
Cmin ↓ 0.80 (0.46-1.38)
Cmin ↓ 0,80 (0,46…1,38)
Cmin ↓ 0.80 (0.73-0.88)
Cmin ↓ 0,80 (0,73…0,88)
Cmin ↓ 0.87 (0.75-1.02)
Cmin ↓ 0,87 (0,75…1,02)
Cmin ↓ 0.88 (0.66-1.17)
Cmin ↓ 0,88 (0,66…1,17)
Cmin ↔ 0 (0.68-1.49)
↔ 0 (0,68…1.49)
Cmin ↔ 0.89 (0.81-0.98)
Cmin ↔ 0,89 (0,81…0,98)
Cmin ↔ 0.97 (0.83-1.15)
Cmin ↔ 0,97 (0,83...1,15)
Cmin ↔ 0.97 (0.86-1.10)
Cmin ↔ 0,97 (0,86...1,10)
Cmin ↔ 1.02 (0.90-1.17)
Cmin ↔ 1,02 (0,90…1,17)
Cmin ↔ 1.07 (0.98-1.17)
Cmin ↔ 1,07 (0,98…1,17)
Cmin ↔ 1.08 (0.98-1.19)
Cmin ↔ 1,08 (0,98…1,19) Cmax ↔ 1,05 (0,95…1,17)
Cmin ↔ 1.08 (1.04-1.14)
Cmin ↔ 1,08 (1,04...1,14)
Cmin ↔ 1.09 (1.01-1.18)
Cmin ↔ 1,09 (1,01…1,18) Cmax ↑ 1,33 (1,21…1,46)
Cmin ↔ 1.10 (1.02-1.19)
Cmin ↔ 1,10 (1,02…1,19)
Cmin ↔ 1.17 (1.10-1.26)
Cmin ↔ 1,17 (1,10…1,26)
Cmin*: 0.41 (0.34, 0.50)
Cmin*: 0,41 (0,34; 0,50)
Cmin*: 3.65 (3.25, 4.11)
Cmin*: 3,65 (3,25; 4,11)
Cmin, ng/mlb
Cmin, ng/mla
Cmin: +--
ANTIHISTAMIINIKUMID
Cmin: 0 10% (j 1 to 0 19)% (CYP3A induction by efavirenz)
Cmin: O 10% (i 1…O 19)% (CYP3A indutseerimine efavirensi poolt)
Cmin: 0 12% (0 24 to j 1) (CYP3A4 induction)
Cmin: O 12% (O 24...i 1)
Cmin: 0 25% (0 14 to 0 34)%
Cmin: O 25% (O 14…O 34)
Cmin: 0 31%
Cmin: O 31
Cmin: 0 32% (0 15 to 0 46) (CYP3A4 and CYP2B6 induction)
Cmin: O 32% (O 15...O 46)
Cmin: 0 43% (0 18 to 0 60)
Cmin: O 43% (O 18...O 60)
Cmin: 0 44% (0 27 to 0 58)
Cmin: O 44% (O 27...O 58)
Cmin: 0 44% Efavirenz: AUC: +-- 20%
Cmin: O 44% Efavirens: AUC: +-- 20
Cmin: 0 45% (0 31 to 0 56)
Cmin: O 45% (O 31...O 56)
Cmin: 0 46% (0 31 to 0 58)
Cmin: O 46% (O 31...O 58)
Cmin: 0.89 (0.75, 1.06)
Cmin: 0,89 (0,75; 1,06)
Cmin: 0.91 (0.71, 1.16)
Cmin: 0,91 (0,71; 1,16)
Cmin: 0.92 (0.80, 1.05)
Cmin: 0,92 (0,80; 1,05)
Cmin: 0.98 (0.67, 1.44)
Cmin: 0,98 (0,67, 1,44)
Cmin: 0.98 (0.82, 1.17
Cmin: 0,98 (0,82; 1,17
Cmin: 091% (088 to 092)
Cmin: O 91% (O 88…O 92)
Cmin: 1.06 (0.88, 1.29)
Cmin: 1,06 (0,88; 1,29)
Cmin: 1.08 (0.93, 1.26)
Cmin: 1,08 (0,93; 1,26)
Cmin: 1.10 (1.03, 1.19)
Cmin: 1,10 (1,03; 1,19)
Cmin: 1.10 (1.04, 1.16)
Cmin: 1,10 (1,04; 1,16)
Cmin: 1.15 (1.02, 1.30)
Cmin: 1,15 (1,02; 1,30)
Cmin: 1.17 (1.03, 1.32)
Cmin: 1,17 (1,03; 1,32)
Cmin: 1.17 (1.10, 1.24)
Cmin: 1,17 (1,10; 1,24)
Cmin: 1.18 (1.09, 1.28)
Cmin: 1,18 (1,09; 1,28)
Cmin: 1.23 (1.09, 1.38)
Cmin: 1,23 (1,09; 1,38)
Cmin: 1.4 (1.35, 1.53)
Cmin: 1,4 (1,35; 1,53)
Cmin: 1.45 (1.25, 1.68)
Cmin: 1,45 (1,25; 1,68)
Cmin: 1.46 (1.12, 1.89)
Cmin: 1,46 (1,12; 1,89)
Cmin: 1.49 (1.33, 1.67)
Cmin: 1,49 (1,33; 1,67)
Cmin: 1.54 (0.46, 5.07)
Cmin: 1,54 (0,46, 5,07)
Cmin: 1.56 (1.41, 1.71)
Cmin: 1,56 (1,41; 1,71)
Cmin: 2.68 (2.42, 2.98)
Cmin: 2,68 (2,42;2,98)
Cmin: j 17%
Cmin: i 17
Cmin: NA Cmax: ↑ 21%
Cmin: pole hinnatud Cmax: ↑ 21
Cmin: NA Cmax: ↓ 14%
Cmin: pole hinnatud Cmax: ↓ 14
Cmin: NA Cmax: ↓ 85%
Cmin: pole hinnatud Cmax: ↓ 85
Cmin: NA Cmax: ↔
Cmin: pole hinnatud Cmax: ↔
Cmin: not determined
Desatsetüüldiltiaseemi Cmin
Cmin: ↑ 1.3-fold (Relative to Indinavir 800 mg TID alone)
Cmin: ↑ 1,3 korda (Asjakohane vaid indinaviiri annuse 800 mg kolm korda ööpäevas puhul)
Cmin: ↑ 13 % (↑ 1 to ↑ 26) (CYP3A4 induction)
Cmin: ↑ 13% (↑ 1...↑ 26) (CYP3A4 indutseerimine)
Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction)
Cmin: ↑ 13% (↑ 1...↑ 26) (CYP3A4 indutseerimine)
Cmin: ↑ 14.4-fold
Cmin: ↑ 14,4 korda
Cmin: ↑ 14.4-fold
pärssimist; need võivad samuti
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Cmin: ↑ 163% (↑ 137 kuni ↑ 197)
Cmin: ↑ 25% (↑ 7 to ↑ 46) (inhibition of CYP-mediated oxidative metabolism)
Cmin: ↑ 25% (↑ 7...↑ 46) (CYP-vahendatud oksüdatiivse metabolismi
Cmin: ↑ 3.5-fold Cmax: ↓ (relative to indinavir 800 mg TID
Cmin: ↑ 3,5 korda Cmax: ↓ (võrrelduna indinaviir 800 mg TID üksi)
Cmin: ↑ 3.5-fold Cmax: ↓ (relative to indinavir 800 mg TID alone)
Cmin: ↑ 3,5 korda Cmax: ↓ (võrrelduna indinaviir 800 mg TID üksi)
Cmin: ↑ 42% (↑ 34 – ↑ 49)
Cmin: ↑ 42% (↑ 34 kuni ↑ 49)
Cmin: ↑ 45% (↑ 27 – ↑ 64)
Cmin: ↑ 45% (↑ 27 kuni ↑ 64)
Cmin: ↑ 47% (↑ 38 – ↑ 57)
Cmin: ↑ 47% (↑ 38 kuni ↑ 57)
Cmin: ↑ 48% (↑ 34 – ↑ 63)
Cmin: ↑ 48% (↑ 34 kuni ↑ 63)
Cmin: ↑ 51% (↑ 37 – ↑ 66)
Cmin: ↑ 51% (↑ 37...↑ 66)
Cmin: ↑ 63% (↑ 45 – ↑ 84)
Cmin: ↑ 63% (↑ 45 kuni ↑ 84)
Cmin: ↑43%
sedatsiooni ja kognitiivse
Cmin: ↑91% (↑ 74 – ↑ 110)
Cmin: ↑ 91% (↑ 74 kuni ↑ 110)
Cmin: ↓ 10% (↑ 1 to ↓ 19) (CYP3A induction by efavirenz)
Cmin: ↓ 10% (↑ 1 kuni ↓ 19) (CYP3A indutseerimine efavirensi poolt)
Cmin: ↓ 10% (↑ 1 to ↓ 19)% (CYP3A induction by efavirenz)
Cmin: ↓ 10% (↑ 1…↓ 19)% (CYP3A indutseerimine efavirensi poolt)
Cmin: ↓ 12 % (↓ 24 to ↑ 1)
Cmin: ↓ 12% (↓ 24...↑ 1) (CYP3A4 indutseerimine)
Cmin: ↓ 12% (↓ 24% to ↑ 1%) (CYP3A4 induction)
Cmin: ↓ 12% (↓ 24...↑ 1)
Cmin: ↓ 15% (↓ 12 to ↓ 9)
Cmin: ↓ 15% (↓ 12 kuni ↓ 9)
Cmin: ↓ 2% (↓ 9 to ↑ 6)
Cmin: ↓ 2% (↓ 9 kuni ↑ 6)
Cmin: ↓ 25% (↓ 14 to ↓ 34) Efavirenz:
Cmin: ↓ 25% (↓ 14 kuni ↓ 34) Efavirens:
Cmin: ↓ 25% (↓ 14 to ↓ 34)% Efavirenz:
Cmin: ↓ 25% (↓ 14…↓ 34)% Efavirens:
Cmin: ↓ 26% (↓ 46 to ↑ 10)
Cmin: ↓ 26% (↓ 46...↑ 10)
Cmin: ↓ 26% (↓ 46 – ↑ 10)
Cmin: ↓ 26% (↓ 46...↑ 10)
Cmin: ↓ 26% Tenofovir: AUC: ↑ 37%
Cmin: ↓ 26% Tenofoviir: AUC: ↑ 37
Cmin: ↓ 31%
Cmin : ↓ 31
Cmin: ↓ 32 % (↓ 15 to ↓ 46)
Cmin: ↓ 44% (↓ 27...↓ 58)
Cmin: ↓ 32 % (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15...↓ 46)
Cmin: ↓ 32% (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15...↓ 46) (CYP3A4 ja CYP2B6
Cmin: ↓ 32% (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15...↓ 46) (CYP3A4 ja CYP2B6 indutseerimine)
Cmin: ↓ 34% (↓ 43 to ↑ 24) Sofosbuvir:
Cmin: ↓ 34% (↓ 43 kuni ↑ 24) Sofosbuviir:
Cmin: ↓ 35 % (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 35% (↓ 24...↓ 44) Efavirens:
Cmin: ↓ 35 % (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 62% (↓ 44...↓ 75)
Cmin: ↓ 35% (↓ 24 to ↓ 44)
Cmin: ↓ 35% (↓ 24...↓ 44)
Cmin: ↓ 35% (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 35% (↓ 24...↓ 44) Efavirens:
Cmin: ↓ 37 % (↓ 17 to ↓ 52) Efavirenz:
Cmax: ↓ 46% (↓ 39…↓ 52)
Cmin: ↓ 37 % (↓ 17 to ↓ 52) Efavirenz:
Cmin: ↓ 37% (↓ 17...↓ 52) Efavirens:
Cmin: ↓ 37% (↓ 17 to ↓ 52)
Cmin: ↓ 37% (↓ 17...↓ 52)
Cmin: ↓ 37% (↓ 17 to ↓ 52) Efavirenz:
Cmin: ↓ 37% (↓ 17...↓ 52) Efavirens:
Cmin: ↓ 42 %* (↓ 31 to ↓ 51)
Cmin: ↓ 42%* (↓ 31...↓ 51)
Cmin: ↓ 43 % (↓ 18 to ↓ 60)
Cmin: ↓ 43% (↓ 18...↓ 60)
Cmin: ↓ 43%
Kaletra’ga koosmanustamisel ei
Cmin: ↓ 43% (↓ 18 to ↓ 60)
Cmin: ↓ 43% (↓ 18...↓ 60)
Cmin: ↓ 43% (↓ 18 to ↓ 60) Efavirenz:
Cmin: ↓ 43% (↓ 18...↓ 60)
Cmin: ↓ 44 % (↓ 27 to ↓ 58)
Cmin: ↓ 44% (↓ 27...↓ 58)
Cmin: ↓ 44% (↓ 27 to ↓ 58) (decrease in itraconazole concentrations: CYP3A4 induction) Hydroxyitraconazole:
Cmin: ↓ 44% (↓ 27...↓ 58) (intrakonasooli kontsentratsiooni vähenemine: CYP3A4 indutseerimine)
Cmin: ↓ 44% Efavirenz: AUC: ↔ 20%
Cmin: ↓ 44% Efavirens: AUC: ↔ 20
Cmin: ↓ 45% (↓ 31 to ↓ 56) Efavirenz:
Cmin: ↓ 45% (↓ 31...↓ 56) Efavirens:
Cmin: ↓ 46 % (↓ 31 to ↓ 58) Efavirenz:
Cmin: ↓ 46% (↓ 31...↓ 58) Efavirens:
Cmin: ↓ 46% (↓ 31 to ↓ 58)
Cmin: ↓ 46% (↓ 31...↓ 58)
Cmin: ↓ 46% (↓ 31 to ↓ 58) Efavirenz:
Cmin: ↓ 46% (↓ 31...↓ 58) Efavirens:
Cmin: ↓ 47 % (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41...↓ 53) (karbamasepiini kontsentratsiooni vähenemine: CYP3A4 indutseerimine; efavirensi kontsentratsiooni vähenemine: CYP3A4 ja CYP2B6 indutseerimine)
Cmin: ↓ 47% (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41...↓ 53) (karbamasepiini kontsentratsiooni langus: CYP3A4 indutseerimine; efavirensi kontsentratsiooni langus: CYP3A4 ja CYP2B6 indutseerimine)
Cmin: ↓ 47% (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41...↓ 53) (karbamasepiini kontsentratsiooni vähenemine: CYP3A4 indutseerimine; efavirensi kontsentratsiooni vähenemine: CYP3A4 ja CYP2B6 indutseerimine)
Cmin: ↓ 52%
Cmax: ↓ 50
Cmin: ↓ 52%
ületab kortikoidide süsteemsete
Cmin: ↓ 57%
koos ulatuslikuma kõrvaltoimete
Cmin: ↓ 62% (↓ 44 to ↓ 75)
Cmin: ↓ 62% (↓ 44...↓ 75)
Cmin: ↓ 63% (↓ 44 to ↓ 75)
Cmin: ↓ 63% (↓ 44...↓ 75)
Cmin: ↓ 8 % (↑ 14 to ↓ 25) Norelgestromin (active metabolite):
Cmin: ↓ 8% (↑ 14…↓ 25)
Cmin: ↓ 8% (↑ 14 to ↓ 25) Norelgestromin (active metabolite): AUC: ↓ 64% (↓ 62 to ↓ 67)
Cmin: ↓ 8% (↑ 14 to ↓ 25) Norelgestromiin (aktiivne metaboliit):
Cmin: ↓ 82% (↓ 79 to ↓ 85)
Cmin: ↓ 82% (↓ 79…↓ 85)
Cmin: ↓ 86% (↓ 80 to ↓ 90) (induction of metabolism)
Cmin: ↓ 86% (↓ 80…↓ 90)
Cmin: ↓ 91% (↓ 88 to ↓ 92) Efavirenz:
Cmin: ↓ 91% (↓ 88…↓ 92) Efavirens:
Cmin: ↔ (CYP3A4 induction)
Cmin: ↔ (CYP3A4 indutseerimine)
CML in ‘chronic’, ‘accelerated’ and ‘blast’ phases.
Kroonilise müeloidse leukeemia krooniline, aktseleratsiooni ja blastne faas.
CML is a leukaemia where granulocytes (a type of white blood cell) start growing out of control.
Krooniline müeloidne leukeemia on leukeemia vorm, mille korral granulotsüüdid (vere valgeliblede liik) hakkavad vohama.
CML with prior imatinib treatment only
62,4 (38,6, 79,1)
CML- CML-
KML- KML
CML-AP n=137 (%)
KML-AF n=137 (%)
CML-CP n=321 (%)
KML-KF n=321 (%)
CNS adverse events
Toimed kesknärvisüsteemile
CNS adverse reactions
Kesknärvisüsteemis avalduvad kõrvaltoimed
CNS bleeding*b, syncope, tremor, amnesia, balance disorder
KNS hemorraagia*b, minestus, treemor, amneesia, tasakaaluhäired
CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions such as optic neuritis and transverse myelitis (see section 4.4)
Kesknärvisüsteemi demüeliniseerivate haiguste nagu sclerosis multiplex’i või lokaalsete demüeliniseerivate seisundite nagu nägemisnärvi põletiku ja seljaajupõletiku nähud (vt lõik 4.4)
CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions, such as optic neuritis and transverse myelitis (see section 4.4)
Kesknärvisüsteemi demüeliniseerivate haiguste nagu sclerosis multiplex’i või lokaalsete demüeliniseerivate seisundite nagu nägemisnärvi põletiku ja seljaajupõletiku nähud (vt lõik 4.4)
CNS depressant medicinal products
Kesknärvisüsteemi depressandid
CNS depression
Kesknärvisüsteemi depressioon
CNS influencing medical products
Kesknärvisüsteemi mõjutavad ravimid
CNS medicinal products
Kesknärvisüsteemi (KNS) mõjutavad ravimid
CNS metastases
Kesknärvisüsteemi metastaasid
CNS TUMOURS
KESKNÄRVISÜSTEEMI KASVAJAD
CNS TUMOURS
KESKNÄRVISÜSTEMI KASVAJAD
CNS-LS scores range from a minimum of 7 (no symptoms) to a maximum of 35.
CNS-LSi punktiskaala ulatub 7st (nähtudeta) kuni maksimaalselt 35ni.
Co administration of PREZISTA co-administered with cobicistat and bosentan is not recommended.
PREZISTA ja kobitsüstaadi manustamine koos bosentaaniga ei ole soovitatav.
CO NDITIO NS OR RESTRIC TIO NS REGARDING SUPPLY AND USE
HANKE- JA KASUTUSTINGIMUSED VÕ I PIIRANGUD
CO NDITIO NS OR RESTRIC TIO NS WITH REGARD TO THE SAFE AND EFFEC TIV E USE O F THE MEDIC INAL PRO DUCT
RAVIMPREPARAADI O HUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED JA PIIRANGUD
Co Wicklow Ireland
Co Wicklow Iirimaa
Co Wicklow Ireland
County Wicklow Iirimaa
Co-
koomat.
Co-
See on
Co- administered
Samaaegselt manustatav ravim
Co- administered Medicinal Product
Samaaegselt manustatav ravim
co- administered with 300 mg
manustatuna koos 300 mg
Co- administration of aliskiren had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics.
Aliskireeni samaaegsel manustamisel puudus oluline toime atorvastatiini, metformiini või amlodipiini farmakokineetikale.
Co- administration of Aptivus and medicinal products that inhibit P-gp may increase tipranavir plasma concentrations.
Aptivus’e ja P-gp-d inhibeerivate ainete koosmanustamisel võib suureneda tipranaviiri plasmakontsentratsioon.
Co- administration of Enviage had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Enviage samaaegsel manustamisel puudus oluline mõju atorvastatiini, valsartaani, metformiini või amlodipiini farmakokineetikale.